Company Performance Metrics
Cameron Strachan: CTO, Co-Founder
Prospect Bio is a synthetic biology company that specializes in building biosensors (living cells) that can measure chemicals. Biosensors are powerful measurement tools which can perform highly complex testing tasks while being near costless to manufacture, field deployable, and massively scalable. As such, Prospect's work generally focusses
on taking broken testing processes - often ones that rely on expensive ($0.5M+), slow, and lab-bound equipment - and replacing them with an affordable, scalable, and on-site biosensor based solutions. The need for improved testing solutions is being driven on a variety of fronts, including growing regulation, increased QC, and concerns about supply chain assurance. This problem set affects numerous industries, as shown by Prospect's diverse partner list which includes one of the three largest wine companies in the the world, a leading California-based Ag company, a prenatal diagnostics maker, and Ginkgo Bioworks.
Prospect Bio has raised $2.8M, and is supported by investors including Illumina, Viking Capital, Stanford-StartX, Digital Sky Technologies, and Rising Tide Fund.
